Compared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key Metrics

By Zacks Equity Research | May 06, 2025, 9:30 AM

For the quarter ended March 2025, Heron Therapeutics (HRTX) reported revenue of $38.9 million, up 12.2% over the same period last year. EPS came in at $0.01, compared to -$0.02 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $37.08 million, representing a surprise of +4.93%. The company delivered an EPS surprise of +200.00%, with the consensus EPS estimate being -$0.01.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Heron Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

  • Net Product Sales- Oncology- SUSTOL: $2.86 million compared to the $2.98 million average estimate based on two analysts. The reported number represents a change of -20.6% year over year.
  • Net Product Sales- Acute Care- APONVIE: $2.26 million versus $1.98 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +352% change.
  • Net Product Sales- Acute Care- ZYNRELEF: $8.04 million versus $9.03 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +60.8% change.
  • Net Product Sales- Oncology- CINVANTI: $25.74 million versus $23.10 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +0.6% change.
View all Key Company Metrics for Heron Therapeutics here>>>

Shares of Heron Therapeutics have returned +8.7% over the past month versus the Zacks S&P 500 composite's +11.5% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
Heron Therapeutics, Inc. (HRTX): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Mentioned In This Article

Latest News

10 hours
10 hours
11 hours
12 hours
12 hours
May-05
May-01
Apr-29
Apr-28
Apr-24
Apr-23
Apr-23
Apr-22
Apr-22
Apr-22